Key result
Circulating exosomes from experimental autoimmune myocarditis mice promoted CD4+ T cell immunometabolic dysfunction and cardiac injury via the transfer of miR-142.
Why the study?
The role of circulating exosomes in experimental autoimmune myocarditis (EAM) immunopathogenesis and CD4+ T cell dysfunction remains elusive.
Circulating exosomes drive CD4+ T cell immunometabolic dysfunction and experimental autoimmune myocarditis pathogenesis via transfer of miR-142, presenting a potential novel therapeutic target.
Suggests exosomal miR-142 inhibition as a strategy in myocarditis models; leaves open human translation and clinical testing.
CD4 + T cells undergo immunometabolic activation to mount an immunogenic response during experimental autoimmune myocarditis (EAM). Exosomes are considered key messengers mediating multiple T cell functions in autoimmune responses. However, the role of circulating exosomes in EAM immunopathogenesis and CD4 + T cell dysfunction remains elusive. Our objective was to elucidate the mechanism of action for circulating exosomes in EAM pathogenesis. We found that serum exosomes harvested from EAM mice induced CD4 + T cell immunometabolic dysfunction. Treatment with the exosome inhibitor GW4869 protected mice from developing EAM, underlying that exosomes are indispensable for the pathogenesis of EAM. Furthermore, by transfer of EAM exosomes, we confirmed that circulating exosomes initiate the T cell pathological immune response, driving the EAM pathological process. Mechanistically, EAM-circulating exosomes selectively loaded abundant microRNA (miR)-142. We confirmed methyl-CpG binding domain protein 2 (MBD2) and suppressor of cytokine signaling 1 (SOCS1) as functional target genes of miR-142. The miR-142/MBD2/MYC and miR-142/SOCS1 communication axes are critical to exosome-mediated immunometabolic turbulence. Moreover, the in vivo injection of the miR-142 inhibitor alleviated cardiac injury in EAM mice. This effect was abrogated by pretreatment with EAM exosomes. Collectively, our results indicate a newly endogenous mechanism whereby circulating exosomes regulate CD4 + T cell immunometabolic dysfunction and EAM pathogenesis via cargo miR-142.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2020) studied Experimental autoimmune myocarditis. Exosome inhibition (GW4869) or miR-142 inhibition vs. PBS or control exosomes was evaluated on EAM progression and CD4+ T cell immunometabolic dysfunction. Circulating exosomes from experimental autoimmune myocarditis mice promoted CD4+ T cell immunometabolic dysfunction and cardiac injury via the transfer of miR-142.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: